Registry of Acute Coronary Syndrome From University Hospital of Vigo

Acute Coronary Syndrome Clinical Trial

— CardioCHUVI  

Official title:

Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03664388
• Other study ID #: Hospital Alvaro Cunqueiro
• Status: Recruiting
• Start date: February 1, 2016
• Est. completion date: February 1, 2020

Study information

• Verified date: September 2018
• Source: Hospital Álvaro Cunqueiro
• Contact: Sergio Raposeiras Roubín, MD, PhD
• Phone: 0034 620170387
• Email: raposeiras26[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Description:

CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018

The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8000
• Est. completion date: February 1, 2020
• Est. primary completion date: September 6, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome.

Exclusion Criteria:

• Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Intervention

Drug:
• Dual antiplatelet therapy with ticagrelor/prasuglre
Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy

Locations

Country	Name	City	State
Spain	Department of Cardiology, Hospital Álvaro Cunqueiro	Vigo	Pontevedra

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Álvaro Cunqueiro

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All cause mortality	Death for any cause	Through study completion, an average of 3 years
Secondary	Reinfarction	New spontaneous acute myocardial infarction	Through study completion, an average of 3 years
Secondary	Bleeding	Any bleeding according to BARC definition (from 1 to 5)	Through study completion, an average of 3 years
Secondary	Ischemic stroke	Ischemic stroke documented in CT	Through study completion, an average of 3 years
Secondary	Cancer	Any type of malignant cancer	Through study completion, an average of 3 years
Secondary	Heart Failure	Heart Failure admissions	Through study completion, an average of 3 years
Secondary	Atrial Fibrillation	Atrial fibrillation documented in ECG	Through study completion, an average of 3 years